Table 3 Generalised linear model investigating association between TOMM40 ‘523’ and age of PD symptom onset in the Australian and PPMI cohorts.

From: The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease

TOMM40 ‘523’

Australian cohort

(n = 226)

PPMI cohort

(n = 368)

Combined cohort

(n = 594)

Naïve+

Corrected#

Naïve+

Corrected#

Naïve+

Corrected#

β-CoE

p

β-CoE

p

β-CoE

p

β-CoE

p

β-CoE

p

β-CoE

p

S/S

−2.008

.267

−1.388

.469

2.580

.040

1.970

.157

0.957

.361

0.728

.525

S/L

−2.222

.331

−1.935

.538

−2.460

.129

−2.759

.181

−2.355

.078

−2.464

.160

S/VL

0.816

.569

1.354

.424

−1.228

.235

−1.301

.259

−0.487

.566

−0.455

.638

L/L

3.399

.403

4.142

.715

0.312

.956

10.474

.214

1.602

.620

8.047

.156

L/VL

1.417

.551

1.717

.583

0.131

.941

1.967

.364

0.587

.682

1.131

.520

VL/VL

0.646

.732

−0.482

.821

0.653

.607

0.082

.952

0.770

.470

0.159

.892

S

−1.261

.416

0.088

.960

−0.561

.613

−0.903

.458

−0.838

.358

−0.631

.536

L

0.087

.958

0.644

.932

−1.149

.338

0.647

.812

−0.687

.485

0.375

.887

VL

1.887

.209

1.480

.370

−0.824

.448

−0.689

.552

0.227

.799

−0.004

.997

  1. +Data taken from GLM without correction for covariates.
  2. #Data taken from GLMs corrected for APOE ε4 load and patient sex.
  3. P and β-CoE values are calculated for the comparison to all other genotypes or alleles.
  4. PPMI, Parkinson’s Progression Markers Initiative; PD, Parkinson’s disease; β-CoE, β-Coefficient; p, statistical significance (p value); S/S, short/short; S/L, short/long; S/VL, short/very long; L/L, long/long; L/VL, long/very long; VL/VL, very long/very long; S, short; L, long; VL, very long; GLM, generalised linear model.
Back to article page